ArticleTherapeutic advances in chronic disease2020
Increases in tumor markers are associated with primary Sjögren's syndrome-associated interstitial lung disease.
Article in Therapeutic advances in chronic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Serum CA125 is independently associated with adverse outcomes in primary Sjögren's syndrome-associated interstitial lung disease: a prospective multicenter cohort study.Respiratory research · 2026Observational
- Biomarkers on Fibrotic Lung Diseases Associated with Usual Interstitial Pneumonia.International journal of medical sciences · 2026Review
- Relationship between clinical characteristics and serum tumor markers in connective tissue disease with interstitial lung disease as the initial manifestation.Archives of medical science : AMS · 2026Article
- Development and external validation of a model for lung transplantation-free survival prediction of primary Sjögren syndrome-associated interstitial lung disease: a prospective cohort study.ERJ open research · 2025Article
- Serum carbohydrate antigen 153 as a predictor of interstitial lung disease associated with rheumatoid arthritis is positively correlated with serum Krebs von den Lungen-6.BMC pulmonary medicine · 2025Article
- Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren's Syndrome: A Systematic Review and Meta-analysis of Observational Studies : Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren's Syndrome.Galen medical journal · 2025Review
- Time-Dependent Mortality Predictors in Primary Sjögren's Syndrome: C-Reactive Protein for Early Risk and Age for Late Outcomes.Journal of inflammation research · 2025Article
- A correlation study of serum tumor markers with systemic lupus erythematosus-associated interstitial lung disease.Frontiers in medicine · 2025Article
- Assessment of tumor biomarkers for prognosis in interstitial lung disease associated with connective tissue disease: a prospective study.Journal of thoracic disease · 2024Article
- CA 15 - 3 in screening for systemic autoimmune rheumatic disease associated interstitial lung disease: a single center cross-sectional study.Rheumatology international · 2024Article
- Screening, diagnosis, and monitoring of interstitial lung disease in autoimmune rheumatic diseases: A narrative review.Revista colombiana de reumatologia · 2024Article
- The characteristics of chest HRCT and pulmonary function tests in lung-onset primary sjogren's syndrome.Immunity, inflammation and disease · 2023Article
- Evaluation of the Clinical Value of KL-6 and Tumor Markers in Primary Sjögren's Syndrome Complicated with Interstitial Lung Disease.Journal of clinical medicine · 2023Article
- Primary-Sjögren's-Syndrome-Related Interstitial Lung Disease: A Clinical Review Discussing Current Controversies.Journal of clinical medicine · 2023Review
- Interstitial Lung Disease and Pulmonary Damage in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023Review
- Understanding Interstitial Lung Diseases Associated with Connective Tissue Disease (CTD-ILD): Genetics, Cellular Pathophysiology, and Biologic Drivers.International journal of molecular sciences · 2023Review
- The significance of elevated tumor markers among patients with interstitial lung diseases.Scientific reports · 2022Article
- Article
- Tumor markers are associated with rapidly progressive interstitial lung disease in adult-dermatomyositis.Clinical rheumatology · 2022Article
- Circulating Th2 cell reduction and Th1/Th2 imbalance are correlated with primary Sjogren's syndrome-associated interstitial lung disease.Arthritis research & therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsInterstitial lung disease (ILD) is the most common type of pulmonary involvement of extraglandular complication in patients with primary Sjögren's syndrome (pSS), but the diagnosis of pSS-associated ILD (pSS-ILD) is still challenging. This study aimed to investigate the levels of serum tumor markers in pSS patients with or without ILD (pSS-non-ILD) and explore its diagnostic value for pSS-ILD.
methodsA total of 168 pSS-ILD patients and age- and sex-matched 538 pSS-non-ILD were recruited. The levels of peripheral tumor markers, including carbohydrate antigen (CA)153, CA125, CA19-9, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), β-human chorionic gonadotropin, alpha fetoprotein, CA724, and complexed prostate specific antigen, the clinical manifestations, and general laboratory indicators were measured and collected.
resultsCompared with pSS-non-ILD, pSS-ILD patients had higher levels of disease activity indicators, such as EULAR Sjögren's syndrome disease activity index, ESR, and CRP, and elevated serum levels of tumor markers: NSE, CEA, CA125, and CA153. The serum levels of CA153 [odds ratio (OR) = 4.521, 95% confidence interval (CI) = [1.871, 10.928)] and CEA [OR = 2.879, 95% CI = (1.305, 6.353)] were significantly correlated with the onset of SS-ILD. CA153 was the only tumor marker with area under receiver operating characteristic curve (AUC) over 0.7 [AUC = 0.743, 95% CI = (0.70, 0.79)].
conclusionTumor markers increased in serum of pSS-ILD patients. Higher CA153 levels are significantly correlated to the increased risk of ILD in patients with pSS and may be directly involved in the pathogenesis of pSS-ILD. Serum CA153 had the best diagnostic value in those tumor markers for pSS-ILD without malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.